Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Low-cost drug discovery with engineered E. coli reveals an anti-mycobacterial activity of benazepril

View ORCID ProfileNadine Bongaerts, View ORCID ProfileZainab Edoo, View ORCID ProfileAyan A. Abukar, View ORCID ProfileXiaohu Song, View ORCID ProfileSebastián Sosa Carrillo, View ORCID ProfileAriel B. Lindner, View ORCID ProfileEdwin H. Wintermute
doi: https://doi.org/10.1101/2021.03.26.437171
Nadine Bongaerts
1INSERM U1284, Université de Paris, Center for Research and Interdisciplinarity (CRI), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nadine Bongaerts
Zainab Edoo
2INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers (CRC), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zainab Edoo
Ayan A. Abukar
1INSERM U1284, Université de Paris, Center for Research and Interdisciplinarity (CRI), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ayan A. Abukar
Xiaohu Song
1INSERM U1284, Université de Paris, Center for Research and Interdisciplinarity (CRI), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xiaohu Song
Sebastián Sosa Carrillo
1INSERM U1284, Université de Paris, Center for Research and Interdisciplinarity (CRI), Paris, France
3USR 3756 IP CNRS, Institut Pasteur, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sebastián Sosa Carrillo
Ariel B. Lindner
1INSERM U1284, Université de Paris, Center for Research and Interdisciplinarity (CRI), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ariel B. Lindner
  • For correspondence: ariel.lindner@inserm.fr jake.wintermute@cri-paris.org
Edwin H. Wintermute
1INSERM U1284, Université de Paris, Center for Research and Interdisciplinarity (CRI), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edwin H. Wintermute
  • For correspondence: ariel.lindner@inserm.fr jake.wintermute@cri-paris.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

ABSTRACT

Whole-cell screening for Mycobacterium tuberculosis (Mtb) inhibitors is complicated by the pathogen’s slow growth and biocontainment requirements. Here we present a synthetic biology framework for assaying Mtb drug targets in engineered E. coli. We construct Target Essential Surrogate E. coli (TESEC) in which an essential metabolic enzyme is deleted and replaced with an Mtb-derived functional analog, linking bacterial growth to the activity of the target enzyme. High throughput screening of a TESEC model for Mtb alanine racemase (ALR) revealed benazepril as a targeted inhibitor. In vitro biochemical assays indicated a noncompetitive mechanism unlike that of clinical ALR inhibitors. This is the first report of an antimicrobial activity in an approved Angiotensin Converting Enzyme (ACE) inhibitor and may explain clinical data associating use of ACE inhibitors with reduced Mtb infection risk. We establish the scalability of TESEC for drug discovery by characterizing TESEC strains for four additional targets.

SIGNIFICANCE STATEMENT The challenge of discovering new antibiotics is both scientific and economic. No simple test can determine if a given molecule will be safe and effective in real human patients. Many drug candidates must therefore be advanced for each new antibiotic that reaches the market - a risky and expensive process.

In this work we use synthetic biology to engineer the common laboratory model bacterium E. coli as a tool for early stage antibiotic discovery. As a proof of concept we expressed a known tuberculosis drug target and found a novel inhibitor: benazepril.

Many other drug targets could be screened similarly using the system that we describe. Because E. coli can be grown safely and cheaply, this approach may help to reduce costs and make drug discovery more accessible.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 27, 2021.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Low-cost drug discovery with engineered E. coli reveals an anti-mycobacterial activity of benazepril
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Low-cost drug discovery with engineered E. coli reveals an anti-mycobacterial activity of benazepril
Nadine Bongaerts, Zainab Edoo, Ayan A. Abukar, Xiaohu Song, Sebastián Sosa Carrillo, Ariel B. Lindner, Edwin H. Wintermute
bioRxiv 2021.03.26.437171; doi: https://doi.org/10.1101/2021.03.26.437171
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Low-cost drug discovery with engineered E. coli reveals an anti-mycobacterial activity of benazepril
Nadine Bongaerts, Zainab Edoo, Ayan A. Abukar, Xiaohu Song, Sebastián Sosa Carrillo, Ariel B. Lindner, Edwin H. Wintermute
bioRxiv 2021.03.26.437171; doi: https://doi.org/10.1101/2021.03.26.437171

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Synthetic Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4682)
  • Biochemistry (10357)
  • Bioengineering (7670)
  • Bioinformatics (26330)
  • Biophysics (13523)
  • Cancer Biology (10683)
  • Cell Biology (15438)
  • Clinical Trials (138)
  • Developmental Biology (8497)
  • Ecology (12820)
  • Epidemiology (2067)
  • Evolutionary Biology (16851)
  • Genetics (11399)
  • Genomics (15478)
  • Immunology (10616)
  • Microbiology (25207)
  • Molecular Biology (10220)
  • Neuroscience (54463)
  • Paleontology (401)
  • Pathology (1668)
  • Pharmacology and Toxicology (2897)
  • Physiology (4342)
  • Plant Biology (9243)
  • Scientific Communication and Education (1586)
  • Synthetic Biology (2557)
  • Systems Biology (6780)
  • Zoology (1466)